Aminolevulinic acid dehydratase deficiency porphyria

Last updated
Aminolevulinic acid dehydratase deficiency porphyria
Other namesPorphyria due to ALA dehydratase deficiency
Autorecessive.svg
ALA dehydratase deficiency has an autosomal recessive pattern of inheritance.
Specialty Gastroenterology, dermatology, medical genetics, endocrinology   OOjs UI icon edit-ltr-progressive.svg
Differential diagnosis Lead poisoning, Tyrosinemia type I

Aminolevulinic acid dehydratase deficiency porphyria (also known as "Doss porphyria", [1] "plumboporphyria", [1] or "ADP" [2] ) is an extremely rare autosomal recessive metabolic disorder that results from inappropriately low levels of the enzyme delta-aminolevulinic acid dehydratase (ALAD), which is required for normal heme synthesis. This deficiency results in the accumulation of a toxic metabolic precursor in the heme synthesis pathway called aminolevulinic acid (ALA). [2] Lead poisoning can also disrupt ALAD and result in elevated ALA causing the same symptoms. [3] [4] [5] [6] [7] Heme is a component of hemoglobin which carries oxygen in red blood cells.

Contents

ALA dehydratase deficiency is a rare cause of hepatic porphyria, meaning that excess porphyrins originate from the liver rather than the bone marrow as in erythropoietic porphyrias. [8] [9]

Signs and symptoms

The clinical presentation of ADP includes a wide range of neurologic and gastrointestinal symptoms. [2] The severity of symptoms is dependent on how functional the ALAD enzyme is in each person. The higher the enzyme activity, the fewer symptoms a person will exhibit and the later they will present. The less functional a person's ALAD enzyme is, the earlier they will present and the more severe their symptoms will be.[ citation needed ]

The disease can present during early childhood (as well as in adulthood) with acute neurologic symptoms that resemble those encountered in acute intermittent porphyria. [1] Patients can also have gastrointestinal symptoms during acute attacks, including abdominal cramping, vomiting, and constipation. [2] Gastrointestinal symptoms can result in failure to thrive and poor weight gain in children. Other symptoms that can occur during an acute attack include a rapid heart beat, high blood pressure, and respiratory difficulties. [2]

Acute attacks can last for weeks and are also called "neurovisceral" attacks due to the neurological complications associated. Patients have reported numbness and tingling in the extremities, seizures, burning pain, poor coordination, inability to move muscles voluntarily, and psychological disturbances. [2] Psychosis, though rare, has occurred in severe instances.

Many triggers have been identified for acute ADP attacks including fasting, a low carb diet, dehydration, alcohol intake, the use of estrogen or progesterone, certain drugs, and other mental and physical stressors. [2]

Genetics

ALA dehydratase deficiency is inherited in an autosomal recessive manner. [8] This means a defective gene responsible for the disorder is located on an autosome, and two copies of the defective gene (one inherited from each parent) are required in order to be born with the disorder. The parents of an individual with an autosomal recessive disorder both carry one copy of the defective gene, but usually do not experience any signs or symptoms of the disorder.[ citation needed ]

In conditions where both parents are carriers:

Diagnosis

To make a diagnosis, the relevant presenting symptoms and a detailed patient history must be considered in addition to obtaining biomarkers in the urine or blood. These biomarkers include urine porphobilinogen (PBG), aminolevulinic acid (ALA), and porphyrins found in blood and urine. [2] PBG levels fluctuate and are best measured during the onset of acute symptoms. [2] ALA levels are increased in ADP and correlate with the severity of the disease. [11]

If levels of porphyrins are significantly elevated, DNA testing can be performed to determine the specific mutations in the ALAD gene. [2] [11] DNA analysis is the most specific test for making a diagnosis of ADP. [11]

Both lead poisoning and succinylacetone, whose levels are increased in tyrosinemia type I, [12] inhibit ALAD. Therefore, these conditions should also be considered when elevated levels of porphyrins are found.

Treatment

Supportive care and treatment of symptoms are the typical management options for ADP. During acute attacks, patients are often hospitalized and given medications for nausea/vomiting, rapid heartbeat, and hypertension while their fluid and electrolyte levels are monitored. [2] Glucose supplementation and intravenous hematin are the mainstay of treatment for acute attacks. [2] Avoiding physical and psychological stressors has been shown to limit the reoccurrence of attacks. [2] [10]

Specific drugs have been identified that can trigger ADP attacks. Inducers of the CYP-450 enzymes are drugs that should be discontinued or avoided in patients with ADP. Drugs included in this category are anti-convulsants like phenytoin and carbamazepine, and other drugs like barbiturates, St. John's wort, and rifampin.[ citation needed ]

Prevalence

The condition is extremely rare, with fewer than 10 cases ever reported. [13] All reported cases have been seen in males. [2] A feature of ADP that separates it from other porphyrias is that it is more prevalent in males than in females. [2] However, it theoretically affects males and females at the same rate. Most cases have been identified in Europe but it can occur in any population. [10]

See also

Related Research Articles

<span class="mw-page-title-main">Porphyria</span> Group of inherited metabolic disorders

Porphyria is a group of liver disorders in which substances called porphyrins build up in the body, negatively affecting the skin or nervous system. The types that affect the nervous system are also known as acute porphyria, as symptoms are rapid in onset and short in duration. Symptoms of an attack include abdominal pain, chest pain, vomiting, confusion, constipation, fever, high blood pressure, and high heart rate. The attacks usually last for days to weeks. Complications may include paralysis, low blood sodium levels, and seizures. Attacks may be triggered by alcohol, smoking, hormonal changes, fasting, stress, or certain medications. If the skin is affected, blisters or itching may occur with sunlight exposure.

<span class="mw-page-title-main">Heme</span> Chemical coordination complex of an iron ion chelated to a porphyrin

Heme, or haem, is a precursor to hemoglobin, which is necessary to bind oxygen in the bloodstream. Heme is biosynthesized in both the bone marrow and the liver.

<span class="mw-page-title-main">Hereditary coproporphyria</span> Medical condition

Hereditary coproporphyria (HCP) is a disorder of heme biosynthesis, classified as an acute hepatic porphyria. HCP is caused by a deficiency of the enzyme coproporphyrinogen oxidase, coded for by the CPOX gene, and is inherited in an autosomal dominant fashion, although homozygous individuals have been identified. Unlike acute intermittent porphyria, individuals with HCP can present with cutaneous findings similar to those found in porphyria cutanea tarda in addition to the acute attacks of abdominal pain, vomiting and neurological dysfunction characteristic of acute porphyrias. Like other porphyrias, attacks of HCP can be induced by certain drugs, environmental stressors or diet changes. Biochemical and molecular testing can be used to narrow down the diagnosis of a porphyria and identify the specific genetic defect. Overall, porphyrias are rare diseases. The combined incidence for all forms of the disease has been estimated at 1:20,000. The exact incidence of HCP is difficult to determine, due to its reduced penetrance.

<span class="mw-page-title-main">Variegate porphyria</span> Medical condition

Variegate porphyria, also known by several other names, is an autosomal dominant porphyria that can have acute symptoms along with symptoms that affect the skin. The disorder results from low levels of the enzyme responsible for the seventh step in heme production. Heme is a vital molecule for all of the body's organs. It is a component of hemoglobin, the molecule that carries oxygen in the blood.

<span class="mw-page-title-main">Porphyria cutanea tarda</span> Medical condition

Porphyria cutanea tarda is the most common subtype of porphyria. The disease is named because it is a porphyria that often presents with skin manifestations later in life. The disorder results from low levels of the enzyme responsible for the fifth step in heme production. Heme is a vital molecule for all of the body's organs. It is a component of hemoglobin, the molecule that carries oxygen in the blood.

<span class="mw-page-title-main">Erythropoietic protoporphyria</span> Medical condition

Erythropoietic protoporphyria is a form of porphyria, which varies in severity and can be very painful. It arises from a deficiency in the enzyme ferrochelatase, leading to abnormally high levels of protoporphyrin in the red blood cells (erythrocytes), plasma, skin, and liver. The severity varies significantly from individual to individual.

<span class="mw-page-title-main">Aminolevulinic acid synthase</span> Class of enzymes

Aminolevulinic acid synthase (ALA synthase, ALAS, or delta-aminolevulinic acid synthase) is an enzyme (EC 2.3.1.37) that catalyzes the synthesis of δ-aminolevulinic acid (ALA) the first common precursor in the biosynthesis of all tetrapyrroles such as hemes, cobalamins and chlorophylls. The reaction is as follows:

Dehydratases are a group of lyase enzymes that form double and triple bonds in a substrate through the removal of water. They can be found in many places including the mitochondria, peroxisome and cytosol. There are more than 150 different dehydratase enzymes that are classified into four groups. Dehydratases can act on hydroxyacyl-CoA with or without cofactors, and some have a metal and non-metal cluster act as their active site.

<span class="mw-page-title-main">Pyruvate kinase deficiency</span> Medical condition

Pyruvate kinase deficiency is an inherited metabolic disorder of the enzyme pyruvate kinase which affects the survival of red blood cells. Both autosomal dominant and recessive inheritance have been observed with the disorder; classically, and more commonly, the inheritance is autosomal recessive. Pyruvate kinase deficiency is the second most common cause of enzyme-deficient hemolytic anemia, following G6PD deficiency.

<span class="mw-page-title-main">Gunther disease</span> Medical condition

Gunther disease is a congenital form of erythropoietic porphyria. The word porphyria originated from the Greek word porphura. Porphura actually means "purple pigment", which, in suggestion, the color that the body fluid changes when a person has Gunther's disease. It is a rare, autosomal recessive metabolic disorder affecting heme, caused by deficiency of the enzyme uroporphyrinogen cosynthetase. It is extremely rare, with a prevalence estimated at 1 in 1,000,000 or less. There have been times that prior to birth of a fetus, Gunther's disease has been shown to lead to anemia. In milder cases patients have not presented any symptoms until they have reached adulthood. In Gunther's disease, porphyrins are accumulated in the teeth and bones and an increased amount are seen in the plasma, bone marrow, feces, red blood cells, and urine.

<span class="mw-page-title-main">Isovaleric acidemia</span> Medical condition disrupting normal metabolism

Isovaleric acidemia is a rare autosomal recessive metabolic disorder which disrupts or prevents normal metabolism of the branched-chain amino acid leucine. It is a classical type of organic acidemia.

<span class="mw-page-title-main">Metabolic disorder</span> Medical condition

A metabolic disorder is a disorder that negatively alters the body's processing and distribution of macronutrients, such as proteins, fats, and carbohydrates. Metabolic disorders can happen when abnormal chemical reactions in the body alter the normal metabolic process. It can also be defined as inherited single gene anomaly, most of which are autosomal recessive.

<span class="mw-page-title-main">Acute intermittent porphyria</span> Medical condition

Acute intermittent porphyria (AIP) is a rare metabolic disorder affecting the production of heme resulting from a deficiency of the enzyme porphobilinogen deaminase. It is the most common of the acute porphyrias.

<span class="mw-page-title-main">Hypoprothrombinemia</span> Medical condition

Hypoprothrombinemia is a rare blood disorder in which a deficiency in immunoreactive prothrombin, produced in the liver, results in an impaired blood clotting reaction, leading to an increased physiological risk for spontaneous bleeding. This condition can be observed in the gastrointestinal system, cranial vault, and superficial integumentary system, affecting both the male and female population. Prothrombin is a critical protein that is involved in the process of hemostasis, as well as illustrating procoagulant activities. This condition is characterized as an autosomal recessive inheritance congenital coagulation disorder affecting 1 per 2,000,000 of the population, worldwide, but is also attributed as acquired.

<span class="mw-page-title-main">Porphobilinogen deaminase</span>

Porphobilinogen deaminase (hydroxymethylbilane synthase, or uroporphyrinogen I synthase) is an enzyme (EC 2.5.1.61) that in humans is encoded by the HMBS gene. Porphobilinogen deaminase is involved in the third step of the heme biosynthetic pathway. It catalyzes the head to tail condensation of four porphobilinogen molecules into the linear hydroxymethylbilane while releasing four ammonia molecules:

<span class="mw-page-title-main">Porphobilinogen</span> Chemical compound

Porphobilinogen (PBG) is an organic compound that occurs in living organisms as an intermediate in the biosynthesis of porphyrins, which include critical substances like hemoglobin and chlorophyll.

Pyruvate carboxylase deficiency is an inherited disorder that causes lactic acid to accumulate in the blood. High levels of these substances can damage the body's organs and tissues, particularly in the nervous system. Pyruvate carboxylase deficiency is a rare condition, with an estimated incidence of 1 in 250,000 births worldwide. Type A of the disease appears to be much more common in some Algonkian Indian tribes in eastern Canada, while the type B disease is more present in European populations.

<span class="mw-page-title-main">Delta-aminolevulinic acid dehydratase</span> Protein-coding gene in the species Homo sapiens

Aminolevulinic acid dehydratase (porphobilinogen synthase, or ALA dehydratase, or aminolevulinate dehydratase) is an enzyme (EC 4.2.1.24) that in humans is encoded by the ALAD gene. Porphobilinogen synthase (or ALA dehydratase, or aminolevulinate dehydratase) synthesizes porphobilinogen through the asymmetric condensation of two molecules of aminolevulinic acid. All natural tetrapyrroles, including hemes, chlorophylls and vitamin B12, share porphobilinogen as a common precursor. Porphobilinogen synthase is the prototype morpheein.

<span class="mw-page-title-main">Harderoporphyria</span> Medical condition

Harderoporphyria is a rare disorder of heme biosynthesis, inherited in an autosomal recessive manner caused by specific mutations in the CPOX gene. Mutations in CPOX usually cause hereditary coproporphyria, an acute hepatic porphyria, however the K404E mutation in a homozygous or compound heterozygous state with a null allele cause the more severe harderoporphyria. Harderoporphyria is the first known metabolic disorder where the disease phenotype depended on the type and location of the mutations in a gene associated with multiple disorders.

<span class="mw-page-title-main">Tyrosinemia type I</span> Medical condition

Tyrosinemia type I is a genetic disorder that disrupts the metabolism of the amino acid tyrosine, resulting in damage primarily to the liver along with the kidneys and peripheral nerves. The inability of cells to process tyrosine can lead to chronic liver damage ending in liver failure, as well as renal disease and rickets. Symptoms such as poor growth and enlarged liver are associated with the clinical presentation of the disease. If not detected via newborn screening and management not begun before symptoms appear, clinical manifestation of disease occurs typically within the first two years of life. The severity of the disease is correlated with the timing of onset of symptoms, earlier being more severe. If diagnosed through newborn screening prior to clinical manifestation, and well managed with diet and medication, normal growth and development is possible.

References

  1. 1 2 3 Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN   978-1-4160-2999-1.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 "ALAD-Deficiency Porphyria (ADP)". American Porphyria Foundation. Retrieved 2020-06-29.
  3. Vannotti A (1954). Porphyrins: Their Biological and Chemical Importance. Hilger & Watts, Hilger Division. p. 126. Indeed, lead poisoning, like all porphyrin diseases, is accompanied by obstinate constipation, nervous lesions, hyperpigmentation and abdominal attacks.
  4. Dancygier H (2009). Clinical Hepatology: Principles and Practice of Hepatobiliary Diseases. Springer Science & Business Media. p. 1088. ISBN   9783642045196. Archived from the original on 8 September 2017. The metabolic abnormalities in lead poisoning are very similar with the ALADP (Doss porphyria)
  5. Akshatha LN, Rukmini MS, Mamatha TS, Sadashiva Rao P, Prashanth B (December 2014). "Lead poisoning mimicking acute porphyria!". Journal of Clinical and Diagnostic Research. 8 (12): CD01-2. doi:10.7860/JCDR/2014/10597.5315. PMC   4316248 . PMID   25653942.
  6. Tsai MT, Huang SY, Cheng SY (2017). "Lead Poisoning Can Be Easily Misdiagnosed as Acute Porphyria and Nonspecific Abdominal Pain". Case Reports in Emergency Medicine. 2017: 9050713. doi: 10.1155/2017/9050713 . PMC   5467293 . PMID   28630774.
  7. Wang, B.; Bissell, D. M.; Adam, M. P.; Ardinger, H. H.; Pagon, R. A.; Wallace, S. E.; Bean LJH; Stephens, K.; Amemiya, A. (2018). "Hereditary Coproporphyria". GeneReviews. PMID   23236641 . Retrieved 28 February 2020. the symptoms in lead poisoning closely mimic those of acute porphyria
  8. 1 2 Jaffe EK, Stith L (February 2007). "ALAD porphyria is a conformational disease". American Journal of Human Genetics. 80 (2): 329–37. doi:10.1086/511444. PMC   1785348 . PMID   17236137.
  9. Doss M, von Tiepermann R, Schneider J, Schmid H (October 1979). "New type of hepatic porphyria with porphobilinogen synthase defect and intermittent acute clinical manifestation". Klinische Wochenschrift. 57 (20): 1123–7. doi:10.1007/bf01481493. PMID   513604. S2CID   11400691.
  10. 1 2 3 4 5 "ALAD Porphyria". NORD (National Organization for Rare Disorders). Retrieved 2020-06-29.
  11. 1 2 3 "ALA Dehydratase Deficiency Porphyria Workup: Laboratory Studies, Other Tests". emedicine.medscape.com. Retrieved 2020-06-29.
  12. Bloomer, Joseph R. "ALAD Porphyria". National Organization for Rare Disorders. Retrieved 5 January 2022.
  13. "Overview of the Porphyrias". Rare Diseases Clinical Research Network . Porphyrias Consortium. n.d. Archived from the original on July 7, 2011. Retrieved March 31, 2021.